Welcome to CDC stacks | Caveat Emptor? Meta-Analysis of Studies Comparing Self-Observed Therapy and Directly Observed Therapy for Tuberculosis - 34637 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Caveat Emptor? Meta-Analysis of Studies Comparing Self-Observed Therapy and Directly Observed Therapy for Tuberculosis
  • Published Date:
    Jun 27 2013
  • Source:
    Clin Infect Dis. 57(7):1062-1063.
Filetype[PDF-39.96 KB]


No Related Documents.
You May Also Like:
  1. TB notes ; 2013, no. 3
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
    Published:
    11/4/2013
    Series:
    TB notes ; 2013, no. 3
    Description:
    Highlights from state and local programs -- DTBE winners of 2013 NCHHSTP honor awards -- Healthy People 2020 progress review -- Blast from the past! TB today! 1990 -- Hot off the press! Quality assurance for TB surveillance data guide and toolit -- T...
    File Type:
    Filetype[PDF - 1.02 MB]
  2. Direct Observation of Treatment Provided by a Family Member as Compared to Non-Family Member among Children with New Tuberculosis: A Pragmatic, Non-Inferiority, Cluster-Randomized Trial in Gujarat, India
    Personal Author:
    Dave, Paresh Vamanrao; Shah, Amar Niranjan; Nimavat, Pankaj B.; Modi, Bhavesh B.; Pujara, Kirit R.; Patel, Pradip; Mehariya, Keshabhai; Rade, Kiran Vaman; Shekar, Soma; Sachdeva, Kuldeep S.; Oeltmann, John E.; Kumar, Ajay M. V.;
    Published:
    Feb 05 2016
    Source:
    PLoS One. 11(2).
    Description:
    Background : The World Health Organization recommends direct observation of treatment (DOT) to support patients with tuberculosis (TB) and to ensure treatment completion. As per national programme guidelines in India, a DOT provider can be anyone who...
    File Type:
    Filetype[PDF - 707.66 KB]
  3. Coming Soon
    Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis
    Personal Author:
    Njie, Gibril J.; Morris, Sapna Bamrah; Woodruff, Rachel Yelk; Moro, Ruth N.; Vernon, Andrew A.; Borisov, Andrey S.;
    Published:
    Jun 14 2018
    Source:
    Am J Prev Med. 55(2):244-252.
    Description:
    Context: : Latent tuberculosis infection diagnosis and treatment is a strategic priority for eliminating tuberculosis in the U.S. The Centers for Disease Control and Prevention has recommended the short-course regimen of 3-month isoniazid-rifapentine...
    Public Access
    Available on:
    August 01, 2019
  4. Directly Observed Therapy and Improved Tuberculosis Treatment Outcomes in Thailand
    Personal Author:
    Anuwatnonthakate, Amornrat; Limsomboon, Pranom; Nateniyom, Sriprapa; Wattanaamornkiat, Wanpen; Komsakorn, Sittijate; Moolphate, Saiyud; Chiengsorn, Navarat; Kaewsa-ard, Samroui; Sombat, Potjaman; Siangphoe, Umaporn; Mock, Philip A.; Varma, Jay K.;
    Published:
    Aug 28 2008
    Source:
    PLoS ONE. 2008; 3(8).
    Description:
    Background : The World Health Organization (WHO) recommends that tuberculosis (TB) patients receive directly observed therapy (DOT). Randomized controlled trials have not consistently shown that this practice improves TB treatment success rates. In T...
    File Type:
    Filetype[PDF - 151.86 KB]
  5. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
    Personal Author:
    Borisov, Andrey S.; Bamrah Morris, Sapna; Njie, Gibril J.; Winston, Carla A.; Burton, Deron; Goldberg, Stefan; Yelk Woodruff, Rachel; Allen, Leeanna; LoBue, Philip; Vernon, Andrew;
    Published:
    Jun 29 2018
    Source:
    MMWR Morb Mortal Wkly Rep. 67(25):723-726.
    Description:
    Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 1...
    File Type:
    Filetype[PDF - 93.58 KB]